%0 Randomized Controlled Trial
%T MWF of the corpus callosum is a robust measure of remyelination: Results from the ReBUILD trial.
%A Caverzasi E
%A Papinutto N
%A Cordano C
%A Kirkish G
%A Gundel TJ
%A Zhu A
%A Akula AV
%A Boscardin WJ
%A Neeb H
%A Henry RG
%A Chan JR
%A Green AJ
%J Proc Natl Acad Sci U S A
%V 120
%N 20
%D 2023 05 16
%M 37155847
%F 12.779
%R 10.1073/pnas.2217635120
%X Myelin repair is an unrealized therapeutic goal in the treatment of multiple sclerosis (MS). Uncertainty remains about the optimal techniques for assessing therapeutic efficacy and imaging biomarkers are required to measure and corroborate myelin restoration. We analyzed myelin water fraction imaging from ReBUILD, a double-blind, randomized placebo-controlled (delayed treatment) remyelination trial, that showed a significant reduction in VEP latency in patients with MS. We focused on brain regions rich in myelin. Fifty MS subjects in two arms underwent 3T MRI at baseline and months 3 and 5. Half of the cohort was randomly assigned to receive treatment from baseline through 3 mo, whereas the other half received treatment from 3 mo to 5 mo post-baseline. We computed myelin water fraction changes occurring in normal-appearing white matter of corpus callosum, optic radiations, and corticospinal tracts. An increase in myelin water fraction was documented in the normal-appearing white matter of the corpus callosum, in correspondence with the administration of the remyelinating treatment clemastine. This study provides direct, biologically validated imaging-based evidence of medically induced myelin repair. Moreover, our work strongly suggests that significant myelin repair occurs outside of lesions. We therefore propose myelin water fraction within the normal-appearing white matter of the corpus callosum as a biomarker for clinical trials looking at remyelination.